+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-tuberculosis Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 112 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 5175881
Factors, such as rising prevalence of tuberculosis, growing initiative from government organization for tuberculosis awareness, collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.

According to the WHO’s 2020 Global Tuberculosis (TB) Report, a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.

Key Market Trends

Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future

The WHO’s strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy. The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.

As per 2019 Global Tuberculosis Report by the WHO, developing countries accounted for most of the global total TB cases, including India (27%), China (9%), Indonesia (8%), and the Philippines (6%). The developing countries mostly rely on the hospitals for healthcare access. Hence high incidence in the regions will boost the market in hospitals and clinics.

Asia-Pacific is Expected to be the Largest Market Over the Forecast Period

As per 2019 Global Tuberculosis Report by the WHO, geographically, most TB cases in 2018 were in the WHO regions of South-East Asia (44%), Africa (24%) and the Western Pacific (18%). As a result, a large number of cases are found in the Asia-Pacific region, which is expected to help the region dominate the market. Moreover, most of the global pharmaceutical companies have penetrated in developing countries like India and China, which is also expected to increase the availability of therapeutics and boost the market growth.

Competitive Landscape

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in the R&D, imore small to mid-sized companies are estimated to enter into the market in the coming future.

Currently, companies such as Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson hold the largest market share.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Tuberculosis
4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness
4.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries
4.3 Market Restraints
4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs
4.3.2 High Cost of MDR and XDR TB Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug Class
5.1.1 Isoniazid
5.1.2 Rifampin
5.1.3 Ethambutol
5.1.4 Pyrazinamide
5.1.5 Fluoroquinolones
5.1.6 Bedaquiline
5.1.7 Amynoglycosides
5.1.8 Thioamides
5.1.9 Cyclic Peptides
5.1.10 Other Drug Classes
5.2 By End User
5.2.1 Hospitals and Clinics
5.2.2 Government Agencies
5.2.3 Non Profit Organizations
5.2.4 Other End Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Lupin Limited
6.1.2 Macleods Pharmaceuticals Ltd
6.1.3 Otsuka Pharmaceutical Co. Ltd
6.1.4 Johnson and Johnson
6.1.5 Pfizer Inc.
6.1.6 Novartis AG

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Otsuka Pharmaceutical Co. Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Novartis AG